Novo Nordisk Shares Post Worst Ever Week as Optimism Wanes

(Bloomberg) – Just six weeks ago, things looked better for Novo Nordisk A/S. Investors were optimistic and the Danish drug producer was briefly in Europe’s most valuable public company. Now, the stock has published the worst week in the record.

After the Ozempic and Wegovy manufacturer cut their forecasts for the year and selecting a company Insider as a new general manager, the share fell 32% this week. After US President Donald Trump asked pharmaceutical companies to reduce American drug prices, the stock was shot on Friday.

This made Novo’s market value equivalent to 213 billion dollars – under companies including Nestle Sa and Astrazeneca PLC. The Danish company left the 10 most valuable stocks in Europe on Friday morning before we reclaim the last home in this list later on the day.

Barclays PLC analyst Emily Field, “Novo for a long time ‘show me’ show me ‘we call the story,” he said. However, Novo wrote with a cheaper, imitator versions of his drugs, and with a new drug pipeline that delayed behind the competitors, “We are struggling to see what investors return to the story”, Fieldd by reducing the stock to equal weight.

Novo’s warning on Tuesday was followed by a turbulent year, which saw that stocks fell 70% of the last summer record. Clinical research results, which are disappointed for experimental drugs, include competition from Eli Lilly & Co. and the task of the former CEO. Novo chose the company Senior Mazi Mike Dustdar as his new leader this week, “But this will not be an easy correction, Bar Barclays Field warned. Novo will report the second quarter results on Wednesday.

An area with a special headache for Novo is competitive for US patients. Compound pharmacies are allowed to make cheaper copies and sell cheaper copies of a drug when brand drugs are insufficient, and this year, although they lose this permission, it continues to be a problem. Novo blamed guidance deduction on non -guided compounds and wider competition.

Many investors and analysts are one of the optimism in which a return of the mood in June is mainly. On Monday, about two -thirds of the analysts monitored by Bloomberg considered the stock as purchasing or equivalent. However, it begins to be careful, on Friday’s market is closed, less than half of the purchasing suggestions.

Read: Novo Nordisk shares are now getting rid of peak pessimism

HSBC analyst Rajesh Kumar said, “We misunderstood Novo,” he said. In a note on Thursday, he cut off the stock to buy, and wrote, “With the ban of the FDA, we did not have the assumption that Novo could regain its market share,” he wrote.

Nevertheless, an investor sees similarities in 2016, known as the world’s largest insulin manufacturer, in 2016, the current situation of Novo and another drug users. Will, Guinness Global Investers’ funding manager, said the company’s competitive position was questioned at that time. Guidance was cut and CEO changed.

“As he rejected Novo innovation and commercial efforts, the share price fell and recovered in an aggressive way, James James said. “Now, for the new CEO, a big mountain climbing for the new CEO to regain and grow the market share and rebuild the trust with investors.”

-Help from Michael Msika, Sagarika Jaisinghani and Blaise Robinson.

There are more stories like this Bloomberg.com